MedTrace Logo

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

NCT02483533 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-12-10

Study results available
· View outcomes & findings →

Summary

LIPO-202-CL-23 is a follow-on study to evaluate the post-treatment safety and duration of clinical effect of LIPO-202 in subjects that completed either the LIPO-202-CL-18 (NCT02397499) or LIPO-202-CL-19 (NCT02398188). No risks related to treatment are anticipated as subjects will not receive additional treatment with LIPO-202 or Placebo for LIPO-202 in this follow-on study.

Conditions

  • Central Abdominal Bulging

Interventions

DRUG

LIPO-202

DRUG

Placebo

Sponsors & Collaborators

  • Neothetics, Inc

    collaborator INDUSTRY

  • Evofem Inc.

    lead INDUSTRY

Principal Investigators

  • Maria Feldman · Neothetics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-12-23
Completion
2016-02-26

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483533 on ClinicalTrials.gov